Generic GLP-1 Drugs Market
完整報告名稱與涵蓋範圍
Generic GLP-1 Drugs Market Size, Share & Trends Analysis Report, By Molecule (Generic Liraglutide, Generic Semaglutide, Generic Exenatide and Other GLP-1 Receptor Agonists), By Indication (Type 2 Diabetes, Obesity and Weight Management), By Route of Administration (Injectable Pen Formulations, Oral Formulations), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The generic GLP-1 drugs market covers off-patent and follow-on versions of glucagon-like peptide-1 receptor agonists for type 2 diabetes and obesity, including generic liraglutide already launched in several markets and generic semaglutide products expected as patent protection lapses in Canada, Brazil, India, China and other territories from 2026 onward. Branded originator products and next-generation multi-agonists are outside the scope, though their pricing and supply behaviour is analysed as a competitive backdrop.
The opportunity is unusual for a generic category because demand for the originator molecules exceeds supply in many countries, leaving large untreated populations sensitive to price. Manufacturers with peptide synthesis capacity, pen-injector partnerships and regulatory experience in complex generics are racing to file, while oral semaglutide generics add a second wave of competition. Patent cliffs are staggered by jurisdiction, so launch sequencing, local manufacturing and pen device sourcing strongly influence who captures early volume. Pricing pressure, pharmacovigilance expectations and reimbursement rules for obesity indications will shape uptake and margins.
Emerging markets in Asia, Latin America and the Middle East will see the earliest generic penetration, followed by Europe and eventually the United States after later patent expiries. Indian, Chinese and multinational generic groups dominate the filing landscape, competing on cost, device quality and supply reliability.
The InsightAce study delivers revenue forecasts in US$ across all molecule, indication, route of administration and distribution channel and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Generic GLP-1 Drugs Market Snapshot
Chapter 4. Global Generic GLP-1 Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Molecule Estimates & Trend Analysis
5.1. Molecule & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Molecule:
5.2.1. Generic Liraglutide
5.2.2. Generic Semaglutide
5.2.3. Generic Exenatide and Other GLP-1 Receptor Agonists
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Type 2 Diabetes
6.2.2. Obesity and Weight Management
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Injectable Pen Formulations
7.2.2. Oral Formulations
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online and Mail-Order Pharmacies
Chapter 9. Generic GLP-1 Drugs Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Dr. Reddy's Laboratories Ltd.
11.2. Cipla Ltd.
11.3. Biocon Ltd.
11.4. Sun Pharmaceutical Industries Ltd.
11.5. Zydus Lifesciences Ltd.
11.6. Lupin Ltd.
11.7. Hetero Labs Ltd.
11.8. Aurobindo Pharma Ltd.
11.9. Teva Pharmaceutical Industries Ltd.
11.10. Sandoz Group AG
11.11. Viatris Inc.
11.12. Hikma Pharmaceuticals PLC
11.13. Amneal Pharmaceuticals, Inc.
11.14. Hangzhou Jiuyuan Gene Engineering Co., Ltd.
11.15. Hybio Pharmaceutical Co., Ltd.
圖表清單 List of Tables & Figures
Table 1. Global Generic GLP-1 Drugs Market Revenue Forecast by Molecule, 2026-2035 (US$ Mn)
Figure 1. Global Generic GLP-1 Drugs Market Segmentation and Scope Overview
Table 2. Global Generic GLP-1 Drugs Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Generic GLP-1 Drugs Market Share by Molecule, 2026 & 2035
Table 3. Global Generic GLP-1 Drugs Market Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Country-by-Country Semaglutide and Liraglutide Exclusivity Expiry Timeline, 2025-2032
Table 4. Global Generic GLP-1 Drugs Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Generic GLP-1 Price Erosion and Volume Expansion Scenarios
Table 5. Global Generic GLP-1 Drugs Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Generic GLP-1 Drugs Growth Opportunity Analysis
Table 6. North America Generic GLP-1 Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Generic GLP-1 Drugs Market Participants
Table 7. Europe Generic GLP-1 Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Generic GLP-1 Drugs Market
Table 8. Asia Pacific Generic GLP-1 Drugs Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Peptide API and Pen-Device Supply Capacity Among Generic Manufacturers
Table 9. Strategic Developments of Leading Generic GLP-1 Drugs Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們